PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

“The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug boosted survival.

In this week’s edition of InnovationRx, we look at the impact of Trump’s proposed budget cuts on biomedical research and global health, news from the ASCO cancer meeting, Summit Therapeutics ...

In this episode, host Shikha Jain, MD, speaks with Sadie Dobrozsi, MD, about the power of information in personalized oncology care, understanding the impacts of genetic testing and more. Sadie ...

As community oncology evolves to deliver chimeric antigen receptor (CAR) T and bispecific therapies closer to home, support is needed to ensure patient access and precision medicine capabilities ...

Huntsman Cancer Institute and University of Utah Health are pleased to announce the appointment of T. Clark Gamblin, MD, MS, MBA, FACS, as the inaugural chief of the Division of Surgical Oncology in ...

Tempus AI said it will work with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology that can gather biological and clinical insights, discover novel drug targets and ...

Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collaborations with AstraZeneca and Pathos AI ...

The agreement with AstraZeneca expands on the strategic partnership between the two companies announced in 2021 and aims to leverage Tempus’ AI-enabled platform and vast repository of multimodal ...